Cardiovascular Risks Not Increased With Denosumab
(MedPage Today) -- AUSTIN, Texas – Denosumab (Prolia, Xgeva) carried no increased risk of cardiovascular disease or stroke when compared with zoledronic acid (Reclast, Zometa) to combat osteoporosis, researchers found.
Compared with zoledronic...
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news
More News: Cardiology | Cardiovascular | Heart | Orthopaedics | Osteoporosis | Reclast | Stroke | Xgeva | Zometa